Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
about
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effectsSalvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disordersNaltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in HumansEfficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace.A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.Drug response profiles to experimental pain are opioid and pain modality specificPharmacology of nonsteroidal antiinflammatory drugs and opioidsEffects of butorphanol on feeding and neuropeptide Y in the rat.Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatmentPharmacological Options for Smoking Cessation in Heavy-Drinking SmokersThe effect of butorphanol postconditioning on myocardial ischaemia reperfusion injury in rats.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Comparison of intramuscular butorphanol and buprenorphine combined with dexmedetomidine for sedation in cats.Fentanyl and Spiradoline Interactions in a Place-Conditioning Black-White Shuttle-Box.
P2860
Q24616738-EFCD67DE-5BB1-49A7-84B2-DF3D84B57B67Q26781580-28084E5F-6DDF-4D78-90E5-67C105DB7A68Q27300685-24AAEEDB-1604-4115-8190-19C997B6A0B1Q30276657-4D10F8D7-6569-400E-9FD7-81B5A05C7367Q33725088-4B2C940B-A82E-4B13-9DF2-CE537F373AF3Q34111646-E4522F74-9D26-4433-8B82-E27E13CA783CQ34644376-BE27F0E9-42A7-4135-AA36-14A5B3FBAFB5Q35882922-A5FF2593-8457-48D7-A522-29556D1833A8Q36057996-B7A31D55-9B8D-4E80-9D11-8B54C40831EEQ36227574-30014401-BAAD-45FF-B767-6660E4C74B1FQ36294656-1CD9BD16-9CFA-4DCB-A621-2725C8397E82Q37595017-FC54DC65-4E16-4952-9BE9-8073F27D50D1Q38379235-400096D5-78D9-4D6F-A8B6-9BEC1F82481BQ47291988-39DEB011-2BF0-4FA7-A19F-D689A86E8CA8Q55379995-924F479C-003F-4FD1-8224-7AF11A63959F
P2860
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@en
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@nl
type
label
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@en
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@nl
prefLabel
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@en
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@nl
P2093
P2860
P1433
P1476
Evaluation of the mu and kappa ...... ferential naltrexone blockade.
@en
P2093
A E Chausmer
E C Strain
G E Bigelow
P2860
P2888
P304
P356
10.1007/S00213-007-0948-Z
P577
2007-10-02T00:00:00Z